tradmap

IVF INVO Fertility, Inc.

$1.99 -1.00%

Data as of close

Healthcare · Surgical & Medical Instruments & Apparatus

INVO Fertility, Inc. (IVF) is a healthcare company in the Surgical & Medical Instruments & Apparatus industry, with a market capitalization of $5 million. Shares last traded at $1.99, 92.0% below their 52-week high. Over the past year the stock is down 92.1%. Net profit margin is -80.2%, below the peer median of -6.9%. Revenue grew 4.7% year over year.

Market Cap
$5M
Shares Out
2.5M
EPS (TTM)
$3620.49
P/E (TTM)*
—
P/S Ratio
0.66
P/B Ratio
0.30
Dividend / Share
—
Dividend Yield
—
52-Week High
$24.75
52-Week Low
$0.53
Volume (venue)
706
Avg Vol (3m, venue)
36,187.222

* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.

Performance

1W
+248.76%
1M
+134.12%
3M
+116.30%
6M
-3.16%
YTD
-47.83%
1Y
-92.14%

Daily candles · volume · SMA(20)/SMA(50) · split-adjusted · Databento EQUS.MINI. IVF split history →

Technicals

RSI (14)
83.20
SMA (50)
$0.88
SMA (200)
$2.41
Price vs SMA50
+125.16%
Price vs SMA200
-17.45%
ATR (14)
$0.16

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$8M
Net Income
-$6M
Gross Margin
6.5%
Operating Margin
-78.7%
Net Margin
-80.2%
Return on Equity
-36.6%
Return on Assets
-23.4%
Current Ratio
0.71
Debt / Equity
0.03
Revenue Growth (YoY)
+4.7%

Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-06-30. Source: SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 $0.35 2026-08-14
Q1 2026 -$3.38 2026-06-22
Q4 2025 (derived) $3662.92 2026-06-02
FY 2025 -$214.64 2026-06-02
Q3 2025 -$39.40 2025-11-17
Q2 2025 -$364.23 2025-08-14

Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.

Full earnings history →

Surgical & Medical Instruments & Apparatus peers

IVF vs 14 industry peers (Surgical & Medical Instruments & Apparatus), by market cap. Data as of close

P/S vs peers
0.66 / 2.81 med
-76% discount
Net margin vs peers
-80.2% / -6.9% med
below median
1–14 of 14
SYKStryker Corporation$116.8B32.254.4413.8%+5.32%
MMM3M$92.2B26.073.6514.0%+2.35%
BSXBoston Scientific$64.3B18.393.0516.6%+5.62%
BDXBecton Dickinson$54.1B57.492.604.5%+0.39%
RMDResMed$32.8B20.565.7127.8%+1.35%
DXCMDexCom$31.6B31.906.1919.4%+2.99%
MDLNMedline Inc.$29.5B—1.04—+4.80%
WSTWest Pharmaceutical Services$28.4B44.468.3618.8%-1.15%
SOLVSolventum$14.4B10.061.7417.3%+4.22%
GKOSGlaukos Corp$14.1B—20.48-24.6%+0.53%
PENPenumbra Inc$12.7B80.679.0211.2%+0.42%
BAXBaxter International$12.5B—1.08-6.2%+5.47%
GMEDGlobus Medical Inc$10.7B19.923.3917.0%+1.81%
PODDInsulet Corporation$10.7B28.393.4912.3%+2.58%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.